# Reactivating NK Cells in Treating Refractory Head and Neck Cancer

> **NCT02507154** · PHASE1,PHASE2 · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 31 (estimated)

## Conditions studied

- Nasopharyngeal Cancer
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Cetuximab + NK cells

## Key facts

- **NCT ID:** NCT02507154
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-07
- **Primary completion:** 2019-08
- **Final completion:** 2019-08
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2018-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02507154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02507154, "Reactivating NK Cells in Treating Refractory Head and Neck Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02507154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*